Login to Your Account

Clinic Roundup

Monday, April 30, 2012
• Savara Pharmaceuticals, of Austin, Texas, reported top-line data from its Phase Ia study of AeroVanc, an inhaled antibiotic. AeroVanc (vancomycin hydrochloride inhalation powder) is a dry powder form of vancomycin in a capsule-based inhaler to treat respiratory methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis (CF).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription